Scientists at Heptares Therapeutics have published the first high-resolution X-ray crystal structure of the complement C5a receptor (a G protein-coupled receptor, GPCR) binding a small molecule ...
Complement represents a chief component of innate immunity in host defense. However, excessive complement activation has been involved in the pathogenesis of inflammatory diseases. In this study, we ...
Sosei Group Corporation ("Sosei"); TSE Mothers Index:4565) announces that scientists at its wholly owned subsidiary, Heptares Therapeutics, have published the first high-resolution X-ray crystal ...
A preclinical mouse study found that Shengjiang San reduced lung inflammation, barrier disruption and neutrophil extracellular trap formation alongside lower C5a/C5aR1-linked responses in LPS-induced ...
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection; Structural modeling provides new insight into izicopan’s differentiated mole ...
Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...
Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...
A study links the high-risk CFH Y402H genotype to granzyme B activity, reduced vitronectin and membrane attack complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results